BI-3802 is a single digit nanomolar BCL6::Co-repressor inhibitor which induces efficacious BCL6 protein degradation in several DLBCL cell lines.

BI-2545 is highly potent inhibitor of Autotaxin (ATX) which can be used to test hypotheses in vitro and in vivo. We also offer BI-3017 as inactive control.

BI 831266 is a potent and selective Aurora B inhibitor that inhibits cell proliferation and could be used as tool compound testing biological hypotheses.

BI-167107 was used to support crystallization of active state β2AR complexes and can be employed as a tool for the crystallization of other beta receptors.

BI 1002494 inhibits SYK with high target potency, good cellular potency, and shows good kinase specificity. It is recommended as in vitro and in vivo tool.

BI-1935 is a potent and selective small molecule inhibitor of the enzyme Soluble epoxide hydrolase (sEH) and can be used as in vitro or in vivo tool compound.

BI-2536 was the first potent and selective PLK1 inhibitor which entered clinical trials. It is a suitable in vitro and in vivo tool to study PLK function.

BI-9627 is a highly potent NHE1 inhibitor with low DDI potential, excellent pharmacokinetics, and good selectivity against NHE2 and NHE3.

BI-4394 is a potent and highly selective inhibitor of MMP-13 that can be used as tool compound to test biological hypotheses in vitro.

BI-1950 is a highly potent inhibitor of LFA-1 and an excellent molecule for testing biological hypotheses in vitro and in vivo.

BI-2540 is a potent inhibitor of HIV non-nucleoside reverse transcriptase (NNRT) and cross-reactive against clinically relevant mutants of reverse transcriptase.

BI 224436 was the first non-catalytic-site integrase inhibitor (NCINI) the clinic. Its excellent potency and ADME profile make it a valuable tool compound.

BI-1388 is a highly selective inhibitor of NS3 protease with nanomolar potency across various HCV genotypes and against resistant mutants D168V and R155K.

BI-1230 is a nanomolar inhibitor of HCV protease and of viral replication with good in vivo PK characteristics.

BI 207127 (Deleobuvir) was an investigational drug against HCV infection, successfully tested in clinical trials, with good tolerability.

BI 653048 is a “dissociated” GR agonist (displaying different transcriptional regulatory profiles between gene transrepression and transactivation).

BI 665915 demonstrates nanomolar FLAP binding potency and is a molecule suitable for testing biological hypotheses in vitro and also in vivo.

BI 99179 is a potent and selective inhibitor for in vitro and in vivo validation of FAS as a therapeutic target for lipid metabolism related diseases.

Chymase plays an important and diverse role in the homeostasis for a number of cardiovascular processes and has been linked to heart failure.

BI-1347 is a selective nanomolar CDK8 inhibitor, suitable for testing biological hypotheses in vitro and also in vivo.

BI-6901 is the first small molecule inhibitor of the Chemokine receptor CCR10. It is a potent and selective compound suitable for in vivo validation.

CCR1 is a key chemokine receptor for human monocyte/macrophage chemotaxis. BI 639667 blocks influx of pro-inflammatory cells to the site of inflammation.

BI-9564 inhibits the human BRD9 with an K_D(BRD9, ITC) of 14 nM, display good cellular potency and an excellent selectivity versus most BET family members.

BI-7273 is a dual BRD7/BRD9 inhibitor (IC₅₀,BRD7 = 117 nM,  IC₅₀,BRD9 = 19 nM (Alpha assay)) and shows excellent selectivity versus the BET family.

BI-3812 is a single digit nanomolar BCL6::Co-repressor inhibitor which also inhibits the BCL6::Co-repressor complex formation in cells.

BI-4659 inhibits Alk5 with an IC₅₀ value of 19 nM and blocks the cellular phosphorylation of Smad2/Smad3 with an EC₅₀ of 185 nM. BI-4659 is a suitable tool for testing biological hypotheses in vitro.